LY3177833 is primarily investigated for its potential therapeutic applications in the field of oncology. It is being studied as an antibody-drug conjugate (ADC) designed to target specific cancer cells, delivering a cytotoxic agent directly to the tumor while minimizing damage to healthy tissues. This approach aims to improve the efficacy and reduce the side effects associated with traditional chemotherapy. Early-phase clinical trials have focused on its use in treating various solid tumors, with researchers exploring its safety, tolerability, and anti-tumor activity. The compound represents a promising avenue in targeted cancer therapy, particularly for patients with advanced or treatment-resistant cancers. Ongoing research continues to evaluate its potential in combination with other treatments to enhance overall therapeutic outcomes.